The absence of a clinically significant effect of food on the single dose pharmacokinetics of Vorapaxar, a PAR-1 antagonist, in healthy adult subjects

Clinical Pharmacology in Drug Development

Volumn 2, Issue 4, 2013, Pages 310-315

  Behm, Martin O ^a   Kosoglou, Teddy ^a   Miltenburg, André M M ^a   Li, Jing ^a   Statkevich, Paul ^a   Johnson Levonas, Amy O ^a   Martinho, Monika ^a   Fackler, Paul ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Food; Interaction; PAR 1; Pharmacokinetics; Vorapaxar

Indexed keywords

VORAPAXAR;

ABDOMINAL PAIN; ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; COUGHING; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOOD DRUG INTERACTION; HUMAN; LIPID DIET; MALE; MAXIMUM PLASMA CONCENTRATION; MUSCLE STRAIN; NAUSEA; PARESTHESIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 84885914301     PISSN: 2160763X     EISSN: 21607648     Source Type: Journal    
DOI: 10.1002/cpdd.38     Document Type: Article

References (6)

1. Chackalamannil S, Wang Y, Greenlee WJ, et al. Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity. J Med Chem. 2008; 51:3061-3064.
2. Chintala M, Vemulapalli S, Kurowski S, et al. SCH 530348, a novel oral antiplatelet agent, demonstrated no bleeding risk alone or in combination with aspirin and clopidogrel in Cynomolgus monkeys [abstract]. Atheroscler Thromb Vasc Biol. 2008; 28:e-136.
3. Kosoglou T, Reyderman L, Tiessen RG, et al. Pharmacodynamics and pharmacokinetics of the novel PAR-1 antagonist vorapaxar (formerly SCH 530348) in healthy subjects. Eur J Clin Pharmacol. 2012; 68:249-258.
4. Reyderman L, Kosoglou T, Tseng J, et al. The effect of food and antacid on pharmacokinetics (PK) of SCH 530348 in healthy subjects [abstract]. Clin Pharmacol Ther. 2009; 85(Suppl. 1):S21.
5. Kosoglou T, Reyderman L, Kasserra C, et al. No differences in the pharmacodynamics and pharmacokinetics of the thrombin receptor antagonist vorapaxar between healthy Japanese and Caucasian subjects. Eur J Clin Pharmacol. 2012; 68:291-300.
6. Becker RC, Moliterno DJ, Jennings LK, et al. Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study. Lancet. 2009; 373:919-928.